New approaches to molecular cancer therapeutics

[1]  P. Hergenrother,et al.  Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy , 2006, Nature chemical biology.

[2]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[3]  M. Lacouture.  Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.

[4]  Ronald A. DePinho,et al.  Model organisms: The mighty mouse: genetically engineered mouse models in cancer drug development , 2006, Nature Reviews Drug Discovery.

[5]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[6]  Jaejoon Won,et al.  Hexachlorophene Inhibits Wnt/β-Catenin Pathway by Promoting Siah-Mediated β-Catenin Degradation , 2006, Molecular Pharmacology.

[7]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Herbert Waldmann,et al.  Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Workman,et al.  Drugging the PI3 kinome , 2006, Nature Biotechnology.

[10]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[11]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[12]  R. Ficner,et al.  Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. , 2006, Journal of biotechnology.

[13]  Thomas LaFramboise,et al.  Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing , 2006, Nature Medicine.

[14]  Rui Alves,et al.  Tools for kinetic modeling of biochemical networks , 2006, Nature Biotechnology.

[15]  M. Drysdale,et al.  Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors , 2006, Molecular Cancer Therapeutics.

[16]  Gerd Ulrich Nienhaus,et al.  Automated high content screening for phosphoinositide 3 kinase inhibition using an AKT 1 redistribution assay. , 2006, Combinatorial chemistry & high throughput screening.

[17]  Paul Workman,et al.  Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. , 2006, Current topics in medicinal chemistry.

[18]  T. Haystead.  The purinome, a complex mix of drug and toxicity targets. , 2006, Current topics in medicinal chemistry.

[19]  S. Friend,et al.  Cancer Biomarkers—An Invitation to the Table , 2006, Science.

[20]  H. Varmus.  The New Era in Cancer Research , 2006, Science.

[21]  Sunkyu Kim,et al.  Validating cancer drug targets , 2006, Nature.

[22]  Paul Workman,et al.  Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. , 2006, Journal of the National Cancer Institute.

[23]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[24]  H. Madhani,et al.  Selective kinase inhibition by exploiting differential pathway sensitivity. , 2006, Chemistry & biology.

[25]  E. Sausville,et al.  Contributions of human tumor xenografts to anticancer drug development. , 2006, Cancer research.

[26]  E. Holland,et al.  Genetically engineered models have advantages over xenografts for preclinical studies. , 2006, Cancer research.

[27]  René Bernards,et al.  An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors , 2006, Nature chemical biology.

[28]  M. Clarke,et al.  Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.

[29]  S. Fesik,et al.  RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors , 2006, Oncogene.

[30]  C. Marshall,et al.  Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen , 2006, Journal of biomolecular screening.

[31]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[32]  Dirk Strumberg,et al.  Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. , 2005, Drugs of today.

[33]  M. Chatterjee‐Kishore,et al.  Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation. , 2005, Drug discovery today.

[34]  L. Vassilev,et al.  Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.

[35]  Christopher W Murray,et al.  Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.

[36]  James A. Lumley,et al.  Compound selection and filtering in library design , 2005 .

[37]  D. Bojanic,et al.  Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.

[38]  P. Johnston,et al.  Genomic profiling of cancer: what next? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Workman,et al.  Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino , 17-Demethoxygeldanamycin in Human Ovarian Cancer , 2005 .

[40]  A. Saghatelian,et al.  Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling , 2005, Nature Biotechnology.

[41]  Paul Workman,et al.  The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[42]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[43]  Derek S. Tan,et al.  Diversity-oriented synthesis: exploring the intersections between chemistry and biology , 2005, Nature chemical biology.

[44]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[46]  Xavier Barril,et al.  Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. , 2005, Journal of medicinal chemistry.

[47]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[48]  Rajiv Sharma,et al.  Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization. , 2005, Current medicinal chemistry.

[49]  Michael S. Cohen,et al.  Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors , 2005, Science.

[50]  P. Workman.  Genomics and the second golden era of cancer drug development. , 2005, Molecular bioSystems.

[51]  Andrew M Davis,et al.  Components of successful lead generation. , 2005, Current topics in medicinal chemistry.

[52]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[53]  C. Hart,et al.  Finding the target after screening the phenotype. , 2005, Drug discovery today.

[54]  C. Lindsley,et al.  The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. , 2005, Current topics in medicinal chemistry.

[55]  Olaf Prien,et al.  Target‐Family‐Oriented Focused Libraries for Kinases—Conceptual Design Aspects and Commercial Availability , 2005, Chembiochem : a European journal of chemical biology.

[56]  P. Marks,et al.  Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid , 2005, Nature Clinical Practice Oncology.

[57]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[58]  Holger Wesche,et al.  High throughput screening for protein kinase inhibitors. , 2005, Combinatorial chemistry & high throughput screening.

[59]  S. Møller,et al.  Identification of Akt Pathway Inhibitors Using Redistribution Screening on the FLIPR and the IN Cell 3000 Analyzer , 2005, Journal of biomolecular screening.

[60]  Kam Y. J. Zhang,et al.  A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.

[61]  György Kéri,et al.  Cellular targets of gefitinib. , 2005, Cancer research.

[62]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[63]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[64]  Christopher T. Walsh,et al.  Lessons from natural molecules , 2004, Nature.

[65]  A. Nassar,et al.  Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. , 2004, Drug discovery today.

[66]  Mark J Ratain,et al.  Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[68]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[69]  Li Xing,et al.  Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.

[70]  D. Swinney,et al.  Biochemical mechanisms of drug action: what does it take for success? , 2004, Nature Reviews Drug Discovery.

[71]  P. Workman,et al.  322 Novel isoquinoline-5-sulfonamides as biochemical and cellular inhibitors of PKB/AKt , 2004 .

[72]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[73]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[74]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[75]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[76]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[77]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[78]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[79]  X. Barril,et al.  Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. , 2004, Chemistry & biology.

[80]  D. Kassel,et al.  Applications of high-throughput ADME in drug discovery. , 2004, Current opinion in chemical biology.

[81]  Paul A Clemons,et al.  Complex phenotypic assays in high-throughput screening. , 2004, Current opinion in chemical biology.

[82]  Li Di,et al.  Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. , 2004, Journal of pharmaceutical sciences.

[83]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[84]  J. Wendoloski,et al.  Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. , 2004, Journal of medicinal chemistry.

[85]  Stuart L Schreiber,et al.  Stuart Schreiber: biology from a chemist's perspective. Interview by Joanna Owens. , 2004, Drug discovery today.

[86]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[87]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[88]  D. Lane,et al.  Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. , 2004, Molecular cancer therapeutics.

[89]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[90]  L. Meijer,et al.  Synthesis and target identification of hymenialdisine analogs. , 2004, Chemistry & biology.

[91]  Sebastian Meier-Ewert,et al.  A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. , 2004, Chemistry & biology.

[92]  T. Möröy,et al.  Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening. , 2004, Angewandte Chemie.

[93]  M. Machida,et al.  Biopharmaceutics Classification by High Throughput Solubility Assay and PAMPA , 2004, Drug development and industrial pharmacy.

[94]  C. Sawyers.  Opportunities and challenges in the development of kinase inhibitor therapy for cancer. , 2003, Genes & development.

[95]  Pamela A. Silver,et al.  A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. , 2003, Cancer cell.

[96]  S. Remiszewski.  The discovery of NVP-LAQ824: from concept to clinic. , 2003, Current medicinal chemistry.

[97]  G. Müller,et al.  Medicinal chemistry of target family-directed masterkeys. , 2003, Drug discovery today.

[98]  R. Hargreaves,et al.  Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[99]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[100]  S. Haggarty,et al.  Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. , 2003, Chemistry & biology.

[101]  A. Ullrich,et al.  Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors* , 2003, The Journal of Biological Chemistry.

[102]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[103]  P. Workman.  How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. , 2003, Current pharmaceutical design.

[104]  L. Elmore,et al.  Telomerase as a Target for Cancer Immunotherapy , 2003, Cancer biology & therapy.

[105]  P. Workman.  Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. , 2003, Molecular cancer therapeutics.

[106]  G. Rishton.  Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.

[107]  P. Workman.  Challenges of PK/PD measurements in modern drug development. , 2002, European journal of cancer.

[108]  B. Riedl,et al.  Design and discovery of small molecules targeting raf-1 kinase. , 2002, Current pharmaceutical design.

[109]  I. Judson.  Gastrointestinal stromal tumours (GIST): biology and treatment. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[110]  K. Shokat,et al.  Novel chemical genetic approaches to the discovery of signal transduction inhibitors. , 2002, Drug discovery today.

[111]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[112]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[113]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[114]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[115]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[116]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[117]  John Mann,et al.  Natural products in cancer chemotherapy: past, present and future , 2002, Nature Reviews Cancer.

[118]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[119]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[120]  N. Rosen,et al.  A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. , 2001, Chemistry & biology.

[121]  D. W. Fry,et al.  Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. , 2000, Anti-cancer drug design.

[122]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[123]  A. Jackman,et al.  Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors. , 1999, Journal of medicinal chemistry.

[124]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[125]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[126]  L. Dick,et al.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. , 1998, Bioorganic & medicinal chemistry letters.

[127]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[128]  Stuart L. Schreiber,et al.  Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP , 1996, Science.

[129]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[130]  Peter G Schultz,et al.  A genome-wide overexpression screen in yeast for small-molecule target identification. , 2005, Chemistry & biology.

[131]  M. Hutzler,et al.  Predicting drug-drug interactions in drug discovery: where are we now and where are we going? , 2005, Current opinion in drug discovery & development.

[132]  P. Workman.  Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. , 2005, Cold Spring Harbor symposia on quantitative biology.

[133]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.